Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Gail J. Roboz et al.|Blood|2017Cited by 1.5k
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell LymphomaElise A. Olsen, Jean Nichols, Madeleine Duvic et al.|Journal of Clinical Oncology|2001Cited by 610